Fate Therapeutics (FATE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Sales | 3,074 | 6,772 | 1,925 | 1,676 | 1,944 |
| Gross Profit | 3,074 | 6,772 | 1,925 | 1,676 | 1,944 |
| Operating Expenses | 55,451 | 51,855 | 52,993 | 49,751 | 53,223 |
| Operating Income | -52,377 | -45,083 | -51,068 | -48,075 | -51,279 |
| Other Income | 4,699 | 6,656 | 3,064 | 3,953 | 6,109 |
| Pre-tax Income | -47,678 | -38,427 | -48,004 | -44,122 | -45,170 |
| Net Income Continuous | -47,678 | -38,427 | -48,004 | -44,122 | -45,170 |
| Net Income | $-47,678 | $-38,427 | $-48,004 | $-44,122 | $-45,170 |
| EPS Basic Total Ops | -0.40 | -0.33 | -0.47 | -0.45 | -0.46 |
| EPS Basic Continuous Ops | -0.40 | -0.33 | -0.47 | -0.45 | -0.46 |
| EPS Diluted Total Ops | -0.40 | -0.33 | -0.47 | -0.45 | -0.46 |
| EPS Diluted Continuous Ops | -0.40 | -0.33 | -0.47 | -0.45 | -0.46 |
| EPS Diluted Before Non-Recurring Items | -0.40 | -0.33 | -0.47 | N/A | N/A |
| EBITDA(a) | $-49,966 | $-43,085 | $-48,878 | $-46,096 | $-49,796 |